AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.

Results: 1-5 of 5

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

LYNPARZA (OLAPARIB) ACCEPTED FOR USE IN SCOTLAND TO TREAT GERMLINE BRCA-MUTATED HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER CHEMOTHERAPY

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

IMFINZI (DURVALUMAB) IN COMBINATION WITH CHEMOTHERAPY RECEIVES POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER

AstraZeneca

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

LYNPARZA (OLAPARIB) ACCEPTED FOR USE IN SCOTLAND TO TREAT GERMLINE BRCA-MUTATED HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER CHEMOTHERAPY

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

IMFINZI (DURVALUMAB) IN COMBINATION WITH CHEMOTHERAPY RECEIVES POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER

Leading UK oncology voices unite to launch pathway to a future where zero people die from cancer